The invention provides peptides derived from a ubiquitous protein, and nucleic acids encoding such peptides. The invention extends to various uses of these peptides and nucleic acids, for example, as antigens for use in vaccines per se and in the generation of antibodies for use in therapeutic drugs for the prevention, amelioration or treatment of infections caused by sepsis-inducing bacteria. The invention particularly benefits immunocompromised hosts such as neonates, babies, children, women of fertile age, pregnant women, foetuses, the elderly and diabetics.

The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0

The application discloses a method of immunising against Staphylococcus aureus infection comprising a step of administering to a human patient a single dose of an immunogenic composition comprising; (i) a Staphylococcus aureus ClfA protein or immunogenic fragment thereof at a dose of 5-50, 10-30, 5-15 or 20-40 μg and (ii) a pharmaceutically acceptable excipient; wherein the pH of the composition is pH 5.0-pH 8.0. The application further discloses an immunogenic composition comprising; (i) a S. aureus Type 5 capsular saccharide conjugated to a carrier protein, (ii) a S. aureus Type 8 capsular saccharide conjugated to a carrier protein, (iii) a ClfA protein or immunogenic fragment thereof, (iv) an alpha toxoid, and (v) a pharmaceutically acceptable excipient; wherein the pH of the immunogenic composition is pH 5.0-pH 8.0

The invention provides monoclonal antibodies that specifically bind to TIGIT. The monoclonal antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The monoclonal antibodies can be used for treatment of cancer and infectious disease, among other applications.

Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.

Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

The disclosure generally relates to the field of prevention and treatment of Staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising Staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the Staphylococcus aureus epitopes and methods for treating Staphylococcus aureus infection with the antibody products.

The disclosure generally relates to the field of prevention and treatment of Staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising Staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the Staphylococcus aureus epitopes and methods for treating Staphylococcus aureus infection with the antibody products.